A peak with no chromophore is a peak with no peak

The consequence is stark and is worth stating without hedging. A method reading at two hundred and eighty nanometres will not see a truncated fragment lacking an aromatic residue, no matter how much of it is present. Such methods circulate in this trade, generally because they were transferred from an application where aromatic selectivity was desirable, and a purity figure generated at that wavelength is not comparable with one generated at two hundred and fourteen. The wavelength is one line on a certificate and its absence makes two numbers incommensurable.

Wavelength, and the impurities it decides to see

The amide bond has a strong absorbance in the far ultraviolet, and peptide methods conventionally read at two hundred and fourteen or two hundred and twenty nanometres to exploit it. The virtue is universality: every peptide-bonded species responds, roughly in proportion to the number of bonds it contains, which is as close to a mass-proportional response as ultraviolet detection gets. The cost is that solvents, additives and dissolved gases also absorb there, so baseline noise is higher and mobile-phase quality matters more.

Aromatic side chains absorb near two hundred and eighty nanometres, where the backbone is essentially transparent. A method reading there sees only species containing tryptophan, tyrosine or phenylalanine, on a quiet baseline. For a peptide with a single tryptophan it is a selective and elegant way to track that residue. As a purity method it is close to indefensible, because any fragment that has lost the aromatic residue is invisible regardless of how much is present.

Certificates reading at two hundred and eighty nanometres do circulate. Readers have sent us several. The Journal’s position is not that such a method is wrong but that it answers a different question, that a purity figure derived from it is not comparable with one derived at two hundred and fourteen, and that the wavelength is one line and belongs on the page. A diode-array detector records everything at once and makes the entire argument moot, which is why we ask whether one was used.

Equal area is not equal mass

Area per cent contains an assumption that is almost never stated: that each species contributes detector signal in proportion to its mass, at the same rate as the parent. In ultraviolet detection that requires equal absorptivity per unit mass, and peptide impurities frequently do not oblige. A truncated fragment missing several amide bonds absorbs less at two hundred and fourteen nanometres per unit mass than the parent; a fragment missing a tryptophan absorbs dramatically less at two hundred and eighty. An oxidation product may absorb slightly more.

The direction of the resulting error is not fixed, which is what makes it awkward. Where impurities under-respond, area per cent overstates purity. Where they over-respond, it understates it. Regulated pharmaceutical practice addresses this by determining relative response factors for known impurities and applying correction factors, or by using an alternative detection principle with a more nearly uniform response — charged aerosol detection and mass-based approaches both aim at this.

Nothing in this market applies correction factors, and it would be unreasonable to expect it, since doing so requires isolated impurity standards. What is reasonable is that the assumption be visible. A purity figure is an area ratio, area ratios approximate mass ratios, and the approximation has not been quantified for the sample in question. Two sentences on a certificate would say so, and would make the number more useful rather than less.¹

Injection load, linearity and the flattened peak

A detector responds linearly to concentration over a defined range and then stops. Overload the column or saturate the detector with too much sample and the main peak flattens at the top, its apex broadens, and its integrated area no longer represents the quantity present. Since the main peak is the numerator and dominates the denominator, distorting it distorts the purity figure — usually downwards, because the flattened peak loses area relative to a properly loaded one.

There is a competing pressure, and it is the reason overloading happens. Small impurities near the reporting threshold need adequate signal-to-noise to be integrated at all, and the way to raise their signal is to inject more sample. A laboratory hunting for 0.05 per cent impurities is tempted towards a load that compromises the main peak. The correct answer in regulated practice is two injections: a small load for the main peak and a larger one for the related-substances profile, with the results combined.

Column overload is a separate phenomenon from detector saturation and produces a characteristic asymmetric fronting peak. Both are visible on the chromatogram to anybody who is shown it, which is one of several reasons the Journal asks for the trace rather than the number. A purity figure calculated from a distorted main peak is arithmetically correct and analytically meaningless, and the only way to know is to look.²

System suitability is the part of a report that says whether the rest of it means anything, and it is the part most often withheld. Tailing factor, replicate precision, resolution of the critical pair: three lines that turn a percentage into a measurement.

A note on method and sourcing

The compendial and regulatory material in this piece is taken from the current general chapters on chromatography and on validation of compendial procedures, from the European Pharmacopoeia chapters on liquid chromatography and on chromatographic separation techniques, and from the harmonised guidelines on analytical validation, on impurities and on specifications for biotechnological products, all read in the original. The separation science is drawn from the chromatography literature, with the peptide-specific behaviour cited where it differs from small-molecule practice.

Where the Journal reports a number it obtained, it states the number of vials, the number of laboratories, whether the vials came from one lot, whether the laboratories knew, and what method parameters were disclosed to us. Where we quote a figure from a certificate we state whether the method was disclosed on it. Where a laboratory or a company answered our questions we distinguish an answer from a refusal and a refusal from a non-response.

Nothing in this department is a recommendation to buy, use or avoid anything. The compounds referred to are sold for research use only and are not approved for human use in any jurisdiction. Corrections and disputes go to standards@compoundjournal.com. Readers with certificates or chromatograms they would like read should write to letters@compoundjournal.com; we do not identify the source of anything sent to us, and we do not publish a reader’s name without permission.

The full spectrum, recorded and discarded

A diode-array detector records ultraviolet absorbance across a wavelength range—commonly 200 to 400 nanometres—at every point in the chromatogram. From that data, two things of immediate value can be extracted. First, the spectrum can be examined at each peak to confirm spectral homogeneity—a pure peak has a spectrum that does not drift across its width, while a co-eluted pair shows a spectrum that changes. Second, the full spectrum can be plotted to reveal absorbers that were not visible at the single monitoring wavelength.³ A 254-nanometre impurity in a sample monitored at 280 nanometres is invisible in the 214-nanometre chromatogram and is therefore invisible in the purity report, until a diode-array scan reveals it.

Almost no research-peptide certificate prints this information. The data exists—it is generated automatically—and its absence from the report is a formatting decision, not a technical limitation. The usefulness of seeing the full spectrum would be apparent on the first certificate where it resolves an otherwise inexplicable discrepancy between the purity and the mass-balance calculation. It is one of the few changes to the standard format that costs nothing and adds information the reader genuinely needs.

Dissolution, pH and what happens before the injection

A peptide in a vial exists in whatever state the manufacturer left it. Reconstituted in water, a hydrophobic sequence may not dissolve completely and the chromatogram will show particles or aggregates. Reconstituted in an acidic buffer, the same sequence dissolves and the chromatogram shows monomer. The purity figure—and the mass balance—changes accordingly. Sample preparation is not one of the twelve values that belong on a method disclosure, and yet it is one of the most consequential, because it determines what population the peptide is actually in when the injection happens.⁴

The trade addresses this by assuming that samples are dissolved in the mobile phase or its aqueous component, and the assumption is sometimes true and sometimes false. A certificate that states how the sample was dissolved, at what concentration, in what solvent and after what incubation time, is one that can be repeated. A certificate that does not is one that will produce different results if the receiving laboratory uses different dissolution practice, which is particularly consequential for poorly soluble sequences.

Integration is where the largest single share of the disagreement lives, and it is a software setting. Raise the threshold and small peaks leave the denominator; widen the solvent-front exclusion and early-eluting material leaves it too. Neither operation touches the sample.

We will keep buying material, submitting it, and printing the method alongside the number, including on the occasions when our own design turns out to have been inadequate. Two of the exercises reported in this department have had their limitations pointed out by readers before we noticed them ourselves, and both corrections are in the log.